Amryt Pharma Plc (NasdaqGS: AMYT) Loss Submission Form

Kuznicki Law is investigating the proposed sale of Amryt Pharma Plc (NasdaqGS: AMYT) to Chiesi Farmaceutici S.p.A.  Under the terms of the proposed transaction, shareholders of Amryt will receive $14.50 in cash plus a Contingent Value Right of up to $2.50 (payable if certain milestones related to Amryt’s product Filsuvez® are achieved) for each American Depositary Share (ADS) of Amryt that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.